No profile data available.
Sana Biotechnology, Inc. (SANA) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in Seattle, United States, with about 194 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$244.17 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $1.38 billion as of December 4, 2025.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of December 4, 2025.
, a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology.
Sana Biotechnology reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$1.38 billion as of December 4, 2025.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Ocular Therapeutix, Inc. (OCUL), Immunocore Holdings plc (IMCR), Nektar Therapeutics (NKTR), Oculis Holding AG (OCS).